Insights & Expertise

Pharmaceutical
Industry Insights

Expert perspectives on technology transfer, regulatory trends, biosimilars, and the future of pharmaceutical science.

Read the Blog Subscribe to Newsletter
Latest Articles

Expert Insights

AI in pharmaceutical regulatory documentation
February 2026 · Regulatory

How AI is Transforming CTD Template Generation

Explore how machine learning models are accelerating regulatory dossier preparation, reducing timelines from weeks to days.

Read More →

The Challenge of Traditional CTD Preparation

Preparing Common Technical Document (CTD) dossiers has traditionally been a time-intensive process requiring weeks of work by regulatory affairs specialists. Each submission must comply with ICH guidelines while addressing market-specific requirements across jurisdictions like the FDA, EMA, Health Canada, and WHO.

AI-Powered Acceleration

At Burrard Pharmaceuticals, we have integrated AI-powered tools into our dossier preparation. These systems analyze existing formulation data, stability studies, and regulatory precedents to generate draft CTD modules in a fraction of the time. Our Pro subscribers receive completed templates within 48 hours.

Quality Without Compromise

Every AI-generated template undergoes review by our senior regulatory scientists before delivery. The technology handles the heavy lifting of formatting, cross-referencing, and compliance checking, while human expertise ensures scientific accuracy and strategic positioning for each market.

Interested in AI-accelerated regulatory submissions? See Tech Transfer & CTD →

← Close article
Biosimilar development trends
January 2026 · Biosimilars

The GLP-1 Revolution: Technology Transfer Opportunities in 2026

With Semaglutide and Tirzepatide dominating the market, we examine the growing opportunity for biosimilar development.

Read More →

A Market Poised for Disruption

The GLP-1 receptor agonist market is projected to exceed $100 billion by 2030, driven by unprecedented demand for diabetes and weight management therapies. As key patents approach expiration, the opportunity for biosimilar development has never been greater.

Technology Transfer: The Fast Track

Rather than investing years in de novo formulation development, pharmaceutical manufacturers can leverage complete technology transfer packages to enter the market faster. Burrard Pharmaceuticals offers ready-to-manufacture packages for Semaglutide, Tirzepatide, Liraglutide, Dulaglutide, and other GLP-1 molecules.

What Is Included

Each technology transfer package includes the master formula, validated analytical methods, ICH-compliant stability data, CTD/eCTD templates, and manufacturing protocols with batch records. Our team provides ongoing support throughout the transfer process.

Ready to enter the GLP-1 market? View Semaglutide package →

← Close article
Sterile injectable manufacturing
December 2025 · Manufacturing

Best Practices for Sterile Injectable Technology Transfer

Key considerations for successful technology transfer of sterile injectable products, from process validation to regulatory filing.

Read More →

The Complexity of Sterile Injectables

Sterile injectable manufacturing is among the most challenging areas in pharmaceutical production. Contamination control, aseptic processing, and stringent regulatory requirements demand meticulous attention to every detail of the manufacturing process.

Critical Success Factors

Successful technology transfer of sterile injectables requires comprehensive documentation covering container closure integrity, sterilization validation, environmental monitoring protocols, and particulate testing methodologies.

Our Approach

Burrard Pharmaceuticals oncology injectable packages include detailed aseptic processing guidelines, validated cleaning procedures for cytotoxic compounds, and equipment qualification protocols. Our 19 oncology molecules each come with production-ready documentation.

Explore our oncology portfolio: View all molecules →

← Close article
Global regulatory landscape
November 2025 · Regulatory

Navigating Multi-Market Regulatory Submissions

Strategies for simultaneous submissions across FDA, EMA, Health Canada, and emerging market authorities.

Read More →

The Multi-Market Challenge

Pharmaceutical companies seeking global market access must navigate a complex web of regulatory requirements. Each authority has unique submission formats, data requirements, and review timelines.

A Unified Strategy

The most efficient approach is to build a core CTD dossier that meets the highest common standard, then adapt it for market-specific requirements. This strategy minimizes rework and allows parallel submissions that can cut years from your global launch timeline.

How Burrard Helps

Our dossier work is prepared for the target authority from the start. For licensed programmes we adapt the CTD for 30+ regulatory authorities, with our team handling the market-specific modifications.

Need multi-market support? Contact us →

← Close article
Ophthalmic pharmaceuticals
October 2025 · Innovation

Ophthalmic Pharmaceuticals: The Next Growth Frontier

An overview of the expanding ophthalmic market and the technology transfer opportunities for biosimilar intravitreal products.

Read More →

A Rapidly Growing Market

The global ophthalmic pharmaceuticals market is expected to reach $45 billion by 2028, driven by aging populations and the rising prevalence of conditions like age-related macular degeneration, diabetic retinopathy, and glaucoma.

Biosimilar Opportunities

Key anti-VEGF biologics including Aflibercept, Ranibizumab, and Faricimab represent enormous biosimilar opportunities as patents expire. Manufacturers who can demonstrate equivalent efficacy and safety stand to capture significant market share.

Our Ophthalmic Portfolio

Burrard Pharmaceuticals offers 11 ophthalmic molecules including Aflibercept, Ranibizumab, Faricimab, Bimatoprost, Latanoprostene Bunod, Netarsudil, Cyclosporine, Lifitegrast, Nepafenac, and Bromfenac.

View products: Aflibercept → · Ranibizumab → · Faricimab →

← Close article
Technology transfer and CTD services
September 2026 · Company News

Tech Transfer & CTD: One Named Programme at a Time

How we now scope technology transfer, dossier work and post-approval support for licensed partners.

Read More →

Why We Changed the Model

After two decades of technology transfer, the partners who bring programmes to market do not need a subscription. They need one named molecule, one territory, and a document set that a receiving site and a regulator can work from. That is what we scope now.

What Is Covered

Technology transfer under three scopes: drug substance supply with fill-and-finish transfer, full manufacturing transfer, or small-molecule and API transfer. CTD/eCTD dossier work for a named molecule and territory, including Module 1–3 compilation, gap review and deficiency-letter responses. Post-approval support for licensed programmes: variations, renewals, annual reports and pharmacovigilance documents.

How It Is Priced

One named programme, scoped in writing, quoted privately. Half in advance, half on delivery. No public price list and no monthly plan.

See Tech Transfer & CTD → · Request a scope →

← Close article